StockTipsArenaBeta

BUY Lupin Limited — Rajesh Palviya, Axis Securities

BUYLupin Limited
Lupin share price target & all analyst calls

byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))17 Aug 2026via CNBC Awaaz.

Entry₹2,259Inferred
Target₹2,320
Total upside +2.70% (call closed)
Stop loss₹2,230-1.28% risk
Exit₹2,23018 Aug 2026, 12:00 pm
Stop-loss hit-1.28%
Follow Rajesh Palviya for new calls(27% target hit, 179 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 1 active Swing call on LUPINSee 152 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 18 Aug 2026
11 supporting1 neutral0 opposing
Supports the BUY call (11)

Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness

NewsEt-Markets·18 Aug · today

(opens in new tab)

Lupin Ltd has received approval from the U.S. FDA for its Pitolisant Tablets. This approval is a significant step for the company's pharmaceutical offerings.

BSE · Company Update·17 Aug · today

(opens in new tab)

Lupin Limited announced that the U.S. FDA has approved its Pitolisant Tablets. This approval is a significant step for the company's product portfolio.

NSE · Press Release·17 Aug · today

(opens in new tab)

Lupin wins US FDA nod for sodium zirconium cyclosilicate to treat hyperkalemia

NewsCnbc-Tv18·10 Aug · 1w ago

(opens in new tab)

Lupin announced that its Sodium Zirconium Cyclosilicate for Oral Suspension has been approved in the United States.

BSE · Company Update·10 Aug · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Lupin Q1 Review: Broad-Based Growth Impresses, But Systematix Sees US Competition Ahead — Check Target Price

NewsNdtv-Profit·10 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Rajesh Palviya, Axis Securities

Every call and its outcome